SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN
Background and Aims: Sofosbuvir + Ribavirin is gold standard for chronic HEP-C patients. We evaluated
the safety and efficacy of sofosbuvir and ribavirin in chronic HEP-C G3 patients.
Methods: We prospectively enrolled 150 patients with chronic HEP- C G3. These patients were
Relapsers/Non-Responders with previous therapy of peg inf and Ribavirin.
Patients with de compensated cirrhosis, platelets count<100, portal vein size >13 mm on ultrasound
were excluded from this study.
Eligible patients were enrolled to receive Sovaldi 400mg daily and Ribavirin 10 mg/Kg body weight for 6
months. These patients were seen in outpatient 4 weekly. They had baseline CBC, TSH, Blood Sugar,
HCV Genotype and HCVPCR quantitative. Each patient had CBC at every 4 weeks. HCVPCR at week 4 , 12
Results: This is our ongoing study we are presenting interim analysis of 100 patients who have
completed 24 weeks of treatment.
Out of 100 patients 75% were male, 25 % were female, median age 48. 98 patients out of 100 (98%)
were PCR negative at week 4, 12 and 24 respectively. Two patients did not havePCRNegative after 8
Weeks of treatment thus treatment was stopped.
All patients are under regular review to monitor HCVPCR6 months after stopping the treatment
(SVR).The most common AEs were nausea, fatigue, and dizziness.
Conclusions: Sof + Riba for HCV-G3 patients is very effective treatment .Most patients achieved RVR
without any major side effects. In our study response rate after completing 24 months of treatment was
98%.Pretty safe safety profile.
Professor Gill and his team is seeing patients in person Observing and Practicing COVID-19 prevention guidelines Physicians rooms and waiting areas Are fully sanitized Patients and attendants are provided masks , gloves and sanitizer at the entry of the premises